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Neuroblastoma is a common solid tumor of
young children
Neuroblastoma is a childhood cancer originating in pluripotent
nerve cells from the neural crest that normally give rise to the
postganglionic sympathetic nervous system. It is the most common
extra-cranial tumor in infants, with 600 new cases diagnosed in the
United States annually. In children neuroblastoma represents I 0
of all tumors, hut is responsible for more than 15% of pediatric
cancer deaths.
One reason for this discrepancy is that in the majority of cases. the
tumor has already metastasized by the time of diagnosis. Unlike
other forms of childhood cancer, advances in theraps. have only
recently begun to yield an increase in survivorship for neurohias
toma patients with the more aggressive forms of disease. Since most
neuroblastoma patients are infants and oung children, the need for
less toxic vet more effective therapy is especially important. Some
of the major challenges that are being addressed are how to balance
the effectiveness of treatment and side effects from radiation!
chemotherapy with long-term patient health. Nev approaches capi
talize on the emerging insights we have gained into the biolog\ of
tins tumor.
Neuroblastoma can regress, or mature to a
benign form
One of the most remarkable and unique features of neuroblastoma
is the occurrence of complete spontaneous regression, or differen
tiation. In fact, despite its aggressive behavior in the majority of
patients. neuroblastoma exhibits the highest rate of spontaneous
regression of any human malignancy. Tumor regression is most
comrnonl observed in infants. while tumors in older patients call
differentiate into benign ganglionenroblastoma or ganglioneurorna.
Neuroblastoma thus provides an interest ini model system for the
de elopment of differentiation therap that could he less debilitat
ing than conentional ehernotherap . et increase un ivorship.
Retinoic acid turns off the N-myc oncogene, a
key step in inducing differentiation
Experinwntail\ . cultured neuroblastoma cells can be induced to
differentiate by a number of agents. including retinoie acid.
phenylacetate, gamma interferon, and vitamin D An early. key
event in the differentiation process. both in tumor cells exposed to
retinoic acid and in normal fetal neuroblasts during neuronal des ci
opment, is a decrease in N-myc oncogene expression. In turn, N
rnvc downregulation immediately precedes growth arrest, and is
followed by morphologic and biochemical maturation (neurite
extension, neurotransmitter biosynthesis, nerve impulse conduc
non). In patient tumors. actis ation of the N-myc oncogcne is
associated with aggressive disease, including tumor metastasis.
resistance to chemotherapy, and rapid tumor progression. In the
laborator . if N—nivc dosvnregulation is prevented by the introduc
tion of exogenous N-myc genes. retinoic acid-induced differentia
non can he blocked. Conversely, decreasing N-rnsc expression by
specific anti—sense oligonucleotides induces tumor cell differentia—
tion even in the absence of any drugs. Thus, regulation of N—myc by
agents such as retinoic acid appears to he an important factor in
determining the biological behavior of this tumor.
Retinoic acid improves patient survival
Clinically, differentiation therapy with retinoic acid has been 5110w n
to have its greatest benefit in tile setting of mmimal residual disease.
following gross tumordebulking by chemotherapy. surgery, autolo
gous stem cell transplant, and radiation therapy. Patients treated
with retinoic acid have a significantly higher survival rate than those
receiving the same therapy without retinoic acid. With multi—modal
conventional therapy, stem cell transplant, and retinoic acid, the
cuiTent 5-year disease-free survival rate has increased to approxi
mately double that of historical controls,
Retinoic acid resistance is associated with
persistent N-myc expression
\\ hile new tindngs on the cluitcal usefulness of retinoie acid
represent encouracing prouress. a cigniticant number of children
nonetheless suffer from tuntor relapse, and sursival in patients w oh
disease prcgrecston is dismal. Based on cell culture and anitrtal
ifiOdds, a potential cause 01’ failure may he the development of
reti note acid resistance. involv itIC loss of tile ability to dovitregulate
‘s-tllve expresston.
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Understanding the molecular regulation of
N-myc transcription
Part of our work at the Cancer Research Center of Hawaii has focused on gaining an
understanding ofthe molecular switch that turns the N-mvc gene off in response to treatment
with retinoic acid. A decrease in N-mvc expression appears to he necessar\ for differentia
non to proceed. Our data cuagest that mutation in the control region, or promoter. of the
N—rn c c’ene result in the recruitment of alternative transcription factors. \—mvc mRNA
production is thusdri en by aditierent set of regulatory proteins than in the normal promoter
with wild type sequence. Unlike the usual proteins, those associating with mutant promoters
may he unaffected by retinoic acid, so that treated cells bearing these mutations can no
longer shut the N—ms c gene off and continue on ith the ditferentiation proerain. Persistent
N-mc expression. even in the face of retinoic acid, would confer a gross th advantage on
these cells, and contribute to their chentotherap\ resistance. Clinically, such factors ma
underlie the process ot tumor relapse and disease progression.
Clinical applications of mechanism-based
research
Through determininc the mechanism of \—mve doss nregulation h retinoie acid we hope to
derive a set of moleculardiagnostics that will allow us to examine tumor DNA lorsignificant
promoter mutations, and use this information to gauge patients’ prognoses with respect to
their potential responsiveness to retinoic acid. Rather than using retinoic acid as the default
drug to deal v ith minimal residual disease, patients at risk for treatment failure could be
triaged to receive new nivestigatis e therapies. Identification of the alternate proteins that
mediate N—ms c transcription in retinoic acid—resistant cells may suggest agents that would
be effective even on N-myc genes with mutant promoters. Ultimately these drugs could be
used in conjunction with retinoic acid, much like we currently combine different conven
tional chemotherapeutic agents. However, an important distinction would be that the goal
ofthiscomhinationdifferentiationtherap would he toeffectcurebv “rehahilitating”cancer
cells, rather than killing them.
Therapy rooted in tumor cell biology, not tumor cell toxicity
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Classified Notices
To place a classified notice:
HMA members—Please send a signed and type
written ad to the HMA office. As a benefit of member
ship. HMA members may place a complimentary one
fme ciassifed ad in HMJ as space is available.
Nonmembers,—Please call 536-7702 for a non-
member form. Rates are $1.50 a word with a minimum
of 20 words or $30. Not commissionable. Payment
must accompany written order.
Office Equipment
EVERYTHING FOR A BRANCH OFFICE— TO DO EXAM
PROCEDURES INCL Dr. & pt. chairs, roller stools, fine
adJust. table. BP rronitor. cstruments. auioc:ave. suopes.
snk - The works. Ouaiity materials. Can ship. Lst available
First 42OO lakes a. jeven nciudes hair transplant and med.
:artoo eQuIp. Big Island 7759OO3 oay 8-10.
Office Space
KAILIJA PROFESSIONAL CENTER—OFFICE SPACE FOR
LEASE. rorn 825sf and up. Ideal for medicai or general off ce
use. Adjacent to municipal parking lot. Please call Janice Wu
(5) at 522-5960.
A%. ‘ We 71 handle your billing
you I p
So L UT ON S toataitoorp.ltnnc.
Maximize Collections
Our knowledge and experience
helps neutralize stall tactics of
insurance companies.
Maximize Reimbursement
Our ongoing review of coding
and charting procedures assist on
in getting masimum compensation.
Secure
tnftincr acccs to
all patient accuunt.s
Specializing
lnrcr,itd l-.icctrontc
.f..l,c,l Records.
Contict Us loda
888-5O62888
infof Jainircstiits.cutn
Even the smallest ads are ceen in the Hawaii Medical Journal.
To place a classified ad call 536.7n02,
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